If you want biotech exposure in a European portfolio, the honest starting point is this: there are very few dedicated biotech UCITS ETFs, the ride is brutal, and this belongs in the satellite sleeve of your portfolio, not the core. I have held sector funds for years, and biotech is the one category where I keep the position small on purpose. The upside stories are real, but so are the multi-year drawdowns that test whether you actually believe in the theme.
The short answer for most European investors is that you access biotech through one broad, US-heavy fund like the iShares Nasdaq US Biotechnology UCITS ETF, and you cap it at roughly 5 to 10 percent of your equity allocation. That is it. The rest of this article explains what these funds hold, why the UCITS menu is so thin, how the index construction changes your risk, and why I would not treat biotech as a substitute for a broad healthcare position.
Related: my Global X ETFs for European investors goes deeper on this.
If this topic matters to your portfolio, start with my cybersecurity ETFs guide.
What a biotech ETF actually holds
Biotechnology funds invest in companies that develop drugs and therapies using biological processes: gene editing, monoclonal antibodies, mRNA platforms, cell therapies. That is a narrower slice than the healthcare sector as a whole. A biotech index leans heavily toward research-stage and mid-stage companies whose value depends on clinical trial outcomes and regulatory approvals rather than on steady product sales.
Selection criteria: the ETF comparison methodology explains exactly how funds earn a place in this comparison.
This matters because the return driver is binary. A phase III trial reads out well and a stock doubles; it fails and the same stock loses half its value in a morning. A biotech ETF smooths this across dozens or hundreds of names, but it cannot smooth away the fact that the whole category swings on drug-approval sentiment, US Food and Drug Administration policy, and the cost of capital. When interest rates rose in 2022, unprofitable biotech was hit hard because its value sits far out in the future. That is the personality of the asset, and no fund structure changes it.
The UCITS options you can actually buy
US investors have a rich biotech menu, including the equal-weight SPDR S&P Biotech fund that traders know as XBI. Europeans cannot buy those US-listed products under the current rules, the same barrier I cover in the cybersecurity ETF guide and across most thematic categories. So your realistic choices are the UCITS-wrapped funds available on European exchanges.
The most established pure-play option is the iShares Nasdaq US Biotechnology UCITS ETF, which tracks the Nasdaq Biotechnology Index. Beyond that, the field thins out quickly. Several “healthcare innovation” or “breakthrough” UCITS ETFs from providers such as L&G, HANetf and iShares include biotech names but blend them with medical devices, diagnostics and digital health, so they are not pure biotech bets. Treat any fund labelled innovation or breakthrough as a broader basket and read its top holdings before you assume it is a biotech proxy.
Because the exact line-up changes as funds launch and close, do not take a ticker on trust. Use the UCITS ETF comparison tool to filter by sector, domicile and ongoing charge, and confirm each fund still exists and is buyable on your broker before you commit. You can also browse the wider ETFs by category overview to see where biotech sits next to other sector and thematic funds.
Index approach: cap-weighted versus equal-weight
The single most important design choice in a biotech fund is how it weights its holdings, because it changes the entire risk profile.
Cap-weighted (large-cap tilt)
The Nasdaq Biotechnology Index, which the main UCITS fund follows, is broadly capitalisation-weighted with some caps. In practice that means a handful of large, often profitable biotech and biopharma giants dominate the top of the fund. This makes it steadier than a small-cap approach, but it also means you are buying mature companies that behave a lot like big pharma, which dilutes the pure innovation exposure some investors are chasing.
Equal-weight (small-cap tilt)
The XBI-style equal-weight approach spreads money evenly, which pushes far more weight into small, clinical-stage companies. That is higher octane: bigger drawdowns, bigger recoveries, and much more sensitivity to trial news and financing conditions. This flavour is largely a US-listed product and is hard to replicate cleanly in a UCITS wrapper today, so most European investors end up with the cap-weighted profile whether they intended to or not.
Biotech UCITS ETFs compared
The figures below are 2026-vintage and illustrative. Verify the current ongoing charge, holdings and replication method on the provider’s official factsheet before buying.
| Feature | Dedicated biotech (cap-weighted Nasdaq Biotech) | Healthcare innovation blend |
|---|---|---|
| Typical TER | ~0.35% (verify) | ~0.45%–0.65% (verify) |
| What it holds | Mostly large/mid US biotech and biopharma | Biotech plus devices, diagnostics, digital health |
| Geography | Heavily US-concentrated | US-led, some global names |
| Volatility | High | High, slightly diversified by sub-theme |
| Purity of biotech bet | Higher | Lower (diluted by other segments) |
| Suggested role | Small satellite (≤5–10%) | Small satellite or broad healthcare tilt |
The risk profile, told honestly
I want to be blunt here because biotech is oversold as a “megatrend” and undersold as a risk. Three features define it. First, volatility is high and drawdowns are long. The category has spent multi-year stretches deeply underwater, and the 2021 to 2023 period was a painful example where small-cap biotech fell heavily and took a long time to recover. If a two-year, 40 percent-plus paper loss would make you sell, this is not your fund.
Second, the outcomes are binary and event-driven. Individual holdings live or die on trial data and approvals, and even a diversified basket reacts sharply to sector-wide sentiment about drug pricing policy and regulation. Third, it is US-concentrated, so you are adding both sector risk and currency risk to a euro portfolio at the same time. That dollar exposure is a genuine factor, and it is worth understanding how it interacts with the rest of your holdings.
None of this means avoid biotech. It means size it like the volatile satellite it is. A position you can hold through a bad two years is worth far more than a larger one you panic-sell at the bottom.
Learning ETFs the slow way?
The free 12-page Starter Kit gets you to a first, sensible portfolio faster: the 7-filter fund shortcut, the 3-question broker matrix, and the 7 costliest beginner mistakes.
Biotech is not the same as broad healthcare
A common mistake is treating a biotech fund as your “healthcare allocation.” They are different animals. Broad healthcare and pharma funds hold large, cash-generative, dividend-paying companies with approved products on the market, so they are far steadier and behave more like a defensive equity sleeve. Biotech sits at the speculative, pre-revenue end of the same industry.
If what you actually want is durable exposure to ageing populations and healthcare spending, a diversified healthcare or pharma fund is the better core holding, and biotech can sit alongside it as a small growth kicker. I go through that distinction in more depth in the guide to the best pharma and healthcare UCITS ETFs. If you are building a thematic satellite bucket, it also pairs naturally with other high-conviction sectors such as robotics and automation ETFs, provided the whole bucket stays modest.
What I would do
For most readers, the practical plan is simple. Keep a broad global equity fund as your core. If biotech genuinely interests you and you can stomach the swings, add the dedicated cap-weighted Nasdaq Biotechnology UCITS ETF as a satellite of no more than 5 to 10 percent, funded from your riskier allocation rather than your defensive one. Accumulating share classes keep things tidy for long-term compounding, and drip-feeding the position over months softens the timing risk in such a volatile category.
If you are risk-averse or near a goal, skip pure biotech entirely and get your exposure indirectly through a broad healthcare fund. And if you find yourself wanting the equal-weight small-cap thrill of XBI, be honest that you are reaching for the highest-risk corner of a high-risk sector, and size accordingly. Confirm the exact ongoing charge and holdings on the official iShares factsheet and check the index rules on the Nasdaq Biotechnology Index page before you buy.
Frequently asked questions
Q: What is the best biotech UCITS ETF for European investors?
A: For most people the practical choice is the dedicated cap-weighted fund tracking the Nasdaq Biotechnology Index, such as the iShares Nasdaq US Biotechnology UCITS ETF, because the pure-play UCITS menu is thin. Confirm the current charge and holdings on the provider factsheet, and treat it as a small satellite rather than a core position.
Q: Can I buy the US biotech ETF XBI in Europe?
A: Generally no. XBI is a US-listed fund and is not available to most European retail investors under current UCITS and PRIIPs rules. Your realistic route to equal-weight small-cap biotech is limited, so most Europeans end up with the cap-weighted Nasdaq Biotechnology exposure instead.
Q: How much of my portfolio should be in biotech?
A: Treat it as a satellite of roughly 5 to 10 percent of your equity allocation at most, and only if you can tolerate deep, multi-year drawdowns. It should never replace your core global fund. Size it so a bad two years would not push you into selling.
Q: What is the difference between a biotech ETF and a healthcare ETF?
A: Biotech funds concentrate on research-stage drug developers whose value hinges on trial results and approvals, so they are far more volatile. Broad healthcare and pharma funds hold large, profitable, often dividend-paying companies with products already on the market, making them a steadier core holding.
Q: What TER should I expect on a biotech UCITS ETF?
A: As a 2026 guide, dedicated biotech funds tend to sit around 0.35 percent, while healthcare-innovation blends often run higher, roughly 0.45 to 0.65 percent. These figures move, so verify the current ongoing charge on the official factsheet before buying.
Q: Why has biotech performed so poorly at times?
A: The sector is sensitive to interest rates because much of its value lies far in the future, and it swings on drug-pricing policy, regulation and trial sentiment. Rising rates and risk-off periods, such as 2022, hit unprofitable biotech especially hard, and recoveries can take years. That volatility is the nature of the asset, not a flaw in any one fund.
This guide is part of our hub on sector and thematic UCITS ETFs — browse the full cluster for related situations.
European UCITS/ETF investor with 11+ years building a global dividend and index portfolio, and founder of Financial Expert Class. I write every guide here from first-hand experience investing across EU brokers and tax regimes — not theory. More about me →